• Criptovalute
  • Mercati Predittivi
  • Notizie
  • Trading Agentico
  • Articoli
  • Leghe

Cerca Criptovalute

Criptovalute di tendenza

CoinRithm

Azienda

Entità legale
Bees-x Limited
Numero società
13308136
Costituita in
England and Wales
Sede legale
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm è un servizio di informazione e ricerca gestito da Bees-x Limited. Non è autorizzato dalla Financial Conduct Authority (FCA) a svolgere attività regolamentate e nulla su questo sito costituisce consulenza finanziaria.

Esplora

CriptovaluteMercati PredittiviNotizieArticoliAgent ArenaLeghe

Funzionalità

CruscottoScambio DimostrativoTrading AgenticoPortafoglioLista di ControlloImpostazioni

Azienda

Chi SiamoMetodologiaTermini di UsoPolitica sulla RiservatezzaPolitica sui CookieDisconoscimento

Assistenza

Supporto ClientiDomande FrequentiKit per sviluppatoriDocumentazione MCP

Social

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Tutti i diritti riservati.
Disponibile su Google PlayScarica su App Store
  • Home
  • MercatiMercati Predittivi
  • Notizie
  • Cruscotto
  1. Mercati Predittivi
  2. Health & Medicine
  3. When will the FDA reclassify BPC-157 to Category 1?
When will the FDA reclassify BPC-157 to Category 1?

When will the FDA reclassify BPC-157 to Category 1?

4.0% (24h)Health & MedicineOne-Off19g
KalshiKalshiVerifica disponibilitàKYC richiesto2% di commissione
Probabilità implicita attuale
Before July
Before July 5%+4.0%
In testa tra 6 esiti
Qualita del mercato

28 / 100

Bassa qualità
Volume 24h

0,1 €

Liquidità

103,8 €

Bassa liquidità
Bid / Ask

1.0% / 6.0%

Spread

500.0%

Spread ampio
Dati di mercato

Aggiornato 2 minuti fa

24 mar 26, 14:001 lug 26, 3:59

Trend

Esito24hProbabilità

Esito scelto

Before July5%

Regole

If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Apr 15, 2026, then the market resolves to Yes.

Kalshi
  • The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
  • Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before May 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jul 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.

Mercati Correlati

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

145,3K €
Sì: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

16,6K €
Sì: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

8,7K €
Sì: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1,3K €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

462,5 €
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

137,8 €
2025: 0%Manifold MarketsMANIFOLD MARKETS

Attivi in questi argomenti

BitcoinBTC$62,871.62+2.52%EthereumETH$1,658.53+1.90%SolanaSOL$65.29+1.89%DogecoinDOGE$0.085+1.76%XRPXRP$1.12+0.73%BNBBNB$596.99+1.87%

Notizie Correlate

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Regole

If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Apr 15, 2026, then the market resolves to Yes.

Kalshi
  • The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
  • Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before May 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jul 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.